Difference between revisions of "Vincristine liposomal (Marqibo)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
Warner-admin (talk | contribs) m |
||
| Line 18: | Line 18: | ||
==Also known as== | ==Also known as== | ||
| − | + | *'''Generic names:''' vincristine sulfate liposome injection, VSLI | |
| + | *'''Brand name:''' Marqibo | ||
==References== | ==References== | ||
| Line 24: | Line 25: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
[[Category:Vesicant chemotherapy]] | [[Category:Vesicant chemotherapy]] | ||
| + | [[Category:Liposomal chemotherapy]] | ||
[[Category:Microtubule inhibitors]] | [[Category:Microtubule inhibitors]] | ||
Revision as of 03:06, 27 October 2017
General information
Class/mechanism: Vinca alkaloid which causes cell cycle arrest in metaphase and inhibits mitosis. Vincristine stabilizes the spindle apparatus by binding to tubulin, alters microtubule structure and function, and inhibits chromosome separation. Marqibo is a formulation of vincristine sulfate that is encapsulated in sphingomyelin/cholesterol liposomes (Optisomes), which are hypothesized to provide improved tissue drug penetration and reduced toxicity.[1][2][3][4]
Route: IV
Extravasation: irritant/vesicant (depending on reference)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information is available in the Vincristine liposomal (Marqibo) package insert.[1]
- Vincristine liposomal (Marqibo) patient drug information (Chemocare)[5]
History of changes in FDA indication
- 8/9/2012: FDA approved "for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies."[1]
Also known as
- Generic names: vincristine sulfate liposome injection, VSLI
- Brand name: Marqibo
References
- ↑ 1.0 1.1 1.2 1.3 Vincristine liposomal (Marqibo) package insert
- ↑ Vincristine liposomal (Marqibo) package insert (locally hosted backup)
- ↑ Marqibo manufacturer's website
- ↑ Jeffrey A. Silverman, Walter Aulitzky, John Lister, Lori Maness, Gary Schiller, Karen Seiter, Scott E. Smith, Wendy Stock, Dina Ben Yehuda, Steven R. Deitcher. Marqibo® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL). ASH 2010 abstract 2142. link to abstract
- ↑ Vincristine liposomal (Marqibo) patient drug information (Chemocare)